Armata Pharmaceuticals received an additional $3.7 million in non-dilutive Department of War funding for AP-SA02’s Phase 3 development. The money matters to investors because it is the program’s first Phase 3-specific support and lifts cumulative non-dilutive funding under the award to approximately $32.4 million.
Key Highlights
- The latest $3.7 million commitment is designated for AP-SA02’s Phase 3 execution.
- Cumulative non-dilutive Department of War support under the award has reached approximately $32.4 million.
- AP-SA02 is being developed alongside antibiotics for complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA.
$3.7M Supports AP-SA02 Phase 3
Armata Pharmaceuticals, Inc. (AMEX: ARMP) is a biotechnology company. The new funding is the first Department of War support specifically tied to Phase 3 execution for AP-SA02. The program is being advanced for AP-SA02, an intravenously administered multi-phage product candidate intended as an adjunct treatment for complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive or methicillin-resistant S. aureus. The funding will support activities connected with the Phase 3 clinical program.
Phase 3 Study Expected in Second Half of 2026
The product candidate has received Qualified Infectious Disease Product, Fast Track and Breakthrough Therapy designations from the FDA. The new commitment extends Department of War support into the Phase 3 stage.
FAQs
Q: How much funding did Armata Pharmaceuticals receive for AP-SA02?
A: Armata Pharmaceuticals received $3.7M in funding for AP-SA02. This is the first Department of War support specifically tied to AP-SA02 Phase 3 execution.
Q: What is Armata Pharmaceuticals using the new funding for?
A: Armata Pharmaceuticals is using the new funding for activities connected with the AP-SA02 Phase 3 clinical program. The funding supports the program’s Phase 3 development.
Q: How much total Department of War support does AP-SA02 have?
A: The article states that the new Department of War funding is $3.7 million. It does not state the total cumulative Department of War support for AP-SA02.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.